compounding pharmacies glp-1 FDA Intensifies Crackdown on Microdose GLP GLP-1 compounding is facing increased

185(2): 2748 Fritz IB, Schulz SK, Srere PA

GHK-Cus primary mechanisms include collagen stimulation (Type I and III synthesis increases of up to 70% in vitro), matrix metalloproteinase regulation (simultaneously activating MMPs for damaged matrix removal while upregulating TIMP-1/TIMP-2 for controlled remodeling), wound contraction promotion, and anti-inflammatory NF-B pathway modulation

We do not have human outcome data, the long-term safety of cumulative copper loading is uncharacterized, and the vials being injected are mostly research-grade products from unregulated suppliers with no sterility guarantee

However, clinicians should remain informed as the field evolves

In contrast, Zepbound (tirzepatide) is emerging as the fastest-growing product